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EGF and TGF-a in the human kidney: Identification of octopal cells in
the collecting duct. Epidermal growth factor (EGF) and transforming
growth factor-alpha (TGF-a) are well-known mitogens expressed in the
kidney. Their human renal cell origin has not been conclusively
identified. The distribution of EGF and TGF-a was investigated immu-
nohistochemically in the adult human kidney in comparison with the
monkey and rodent kidney. In humans, as in the monkey, two variants
of EGF immunoreactivity were detected. One was present along the
apical cell surfaces and diffusely in the cytoplasm of the thick ascending
limb (TAL), co-localizing with Tamm-Horsfall protein, and in the distal
convoluted tubule (DCT). The other occurred as overall membranous
staining in the connecting tubule and cortical collecting duct (CD), and
mainly as basal staining in the rest of the CD. The EGF stained cells in
the cortical and outer medullary CD reached a diameter of 40 and
were identified as intercalated or dark cells; they displayed a peculiar
octopus-like shape, bearing long lateral extensions that stretched un-
derneath and between 20 surrounding smaller negative cells. Cytoplas-
mic TGF-a staining appeared in the DCT and decreased further on. In
conclusion: (1) the normal human distal nephron displayed EGF and
TGF- immunoreactivity in a partly complementary segmental and
subcellular distribution pattern, partly differing from that in rodents. (2)
EGF immunostaining revealed the presence of long lateral projections
on CD intercalated cells; this peculiar morphology suggests a modula-
tory role within the CD epithelium, possibly involving the EGF immu-
noreactivity on their surface.
Since 1938 it has been known that urine of pregnant women
contains a substance, urogastrone, that exerts a potent inhibi-
tory effect on gastric acid secretion [1]. In 1975 it was demon-
strated that this substance is identical to epidermal growth
factor (EGF) [2, 3], which had been discovered thirteen years
earlier in extracts from the male mouse submaxillary gland [4].
EGF appears in normal human urine in appreciable amounts
[5]; a renal origin of this urinary EGF is suggested by the finding
that its expression in the human kidney by far exceeds that in
other tissues [6] and by its comparatively low plasma concen-
tration [5]. Transforming growth factor-alpha (TGF-a) could
not be detected in human urine in normal conditions [7],
although low expression levels have been demonstrated in renal
tissue [8].
EGF and TGF-a belong to the family of EGF-like growth
factors, together with amphiregulin, vaccinia virus growth
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factor, and heparin-binding EGF-like growth factor. Not only
do they share 40% sequence homology, they are also indistin-
guishable with respect to the binding to and activation of the
same receptor. The human peptides are proteolytic fragments
of separate transmembrane precursors of 1,207 [9] and 160
amino acids [10], respectively. Consequently, mature EGF and
TGF-a constitute only 5% and 31% of their precursor sequence.
Comparison between the urinary levels of mature EGF and the
amount of EGF precursor found in the kidney suggests a high
precursor turnover [11, 12].
The documented in vitro biological effects of EGF and TGF-a
on kidney cells are very similar. They both exert a mitogenic
activity on several types of cultured renal epithelial cells [13—16]
including human kidney epithelial cells [17—19], as well as on
mesenchymal cells [20]. They also enhance renal cell differen-
tiation [21, 22]. Such activities are of potential importance
during kidney regeneration, but quite unexpectedly it appears
that several types of acute renal failure in the rat are accompa-
nied by a dramatic decrease instead of an increase in the renal
expression of EGF [23—27]. Furthermore, exogenous EGF has
a rather limited beneficial effect on morphological and func-
tional recovery of the kidney [27—30]. As a result, despite the
established reputation of EGF as a growth factor in vitro, the
biological role for the EGF of renal origin in vivo is not known.
The same holds true for TGF-a.
Identification of the cells producing these biologically impor-
tant peptides in the kidney constitutes an essential element in
the search for their possible biological function within this
organ. Conclusive immunohistochemical and in situ hybridiza-
tion data show that the TAL and early DCT are the sites of EGF
expression in the rat and mouse nephron [31—33]. In contrast,
and although the link between EGF and the human kidney is
already 55 years old, available data on the identity of the cells
that produce this EGF in the human nephron are still largely
inconclusive. Also, the expression of TGF-a in the normal
human kidney has not been thoroughly investigated. As a
result, current thinking on the role of renal EGF, either as a
mitogen or as a modulator of a yet unidentified distal tubular
function(s), departs from the existence of an interspecies ho-
mology in cellular and subcellular distribution of EGF between
rodents and other species [34, 35], but such a homology has not
been demonstrated. Therefore, the primary aim of the present
study was the identification of the nephron segments and cell
types that express EGF and TGF-a in the adult human kidney.
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Methods
Tissues
Adult normal human kidney tissue was obtained: (1) from a
live 44-year-old female multi-organ donor, whose kidneys were
refused for transplantation because of their spotty appearance
after perfusion, and (2) at the moment of surgery from patients
with renal cancer involving no more than 50% of the affected
kidney (N = 10) while having no proteinuria and a normal renal
function (as determined from the serum creatinine concentra-
tion and calculated creatinine clearance according to the Cock-
croft-Gault formula including corrections for age and sex [361).
The latter samples were taken at least 5 centimeters removed
from the tumor and displayed a normal morphology upon light
microscopical examination. One ureter specimen was also
investigated. All samples were processed within 15 minutes
after removal. Tissues were cut into 1 to 2 mm thick slices,
which were fixed during 1.5 hours at room temperature in
Formol-calcium fixative [4% formaldehyde (BDH Chemical
Ltd, Poole, UK) in 0.1 M sodium cacodylate buffer, pH 7.4,
containing 1% CaCl2], and were embedded in low-melting point
(49°C) paraffin (BDH Chemical Ltd). Formol-calcium fixed
paraffin-embedded kidney tissue from a Java monkey (Macaca
fascicularis), a Wistar rat, and a mouse were used in compari-
son. Alternative tissue processing procedures included: (1)
snap-freezing of tissue slices between copper blocks cooled in
liquid nitrogen, and fixation of air-dried 6-/.Lcryostat sections in
chloroform-aceton (1/1) during five minutes at room tempera-
ture; (2) fixation in periodatellysine/paraformaldehyde (PLP)
fixative during four hours at room temperature and embedding
in low-melting point paraffin.
Histotopographic terminology
The standard nomenclature and abbreviations for the differ-
ent kidney structures, as proposed by Kriz and Bankir [37] on
behalf of the Renal Commission of the International Union of
Physiological Sciences, were used throughout this study. They
are: C, cortex; CD, collecting duct; CNT, connecting tubule;
DCT, distal convoluted tubule; IM, inner medulla; ISOM, inner
stripe of outer medulla; MR, medullary ray; OM, outer medulla;
OSOM, outer stripe of outer medulla; PCT, proximal convo-
luted tubule, also designated as the SI and S2 segments; PST
proximal straight tubule, also called the S3 segment; TAL, thick
ascending limb; TL, thin limb.
Identification of nephron segments and particular cell types
The identity of the segments displaying distinct staining
patterns for EGF and TGF-a was established from partial
nephron reconstructions using a set of 30 consecutive sections,
and from tubular profiles in which the transition from one
segment to another could be seen. Additional morphological
elements of discrimination were the histotopographical local-
ization and the geometry of tubular cross sections. The identity
of the segments was further confirmed on adjacent sections by
determining the presence or absence of a set of differentiation
markers that cover the entire nephron: alkaline phosphatase
and gamma-glutamyl transpeptidase for the proximal tubule;
Tamm-Horsfall protein (THP) for the TAL; epithelial mem-
brane antigen and peanut agglutinin binding for the entire distal
tubule, as described in a previous study [38]. Histochemical
staining for carbonic anhydrase enzyme activity was used to
identify the intercalated cells in the CD [35].
Immunohistochemical staining
For EGF, six different commercially-available primary anti-
sera or antibodies were compared on cryostat sections and on
paraffin sections without or with trypsin pretreatment: (1) an
affinity-purified rabbit antiserum against recombinant human
EGF (Ab-3; Oncogene Science, Inc., Uniondale, New York,
USA) showing no cross reactivity with human TGF-a, diluted
1/100 to 1/1,000; (2) a rabbit antiserum against recombinant
human EGF (Ab 1910, Chemicon International, Inc., Temec-
ula, California, USA), diluted 1/100; (3) a mouse monoclonal
antibody against human EGF (MAb 144-8, Santa Cruz Biotech-
nology, Inc., Santa Cruz, California, USA) not cross reacting
with human TGF-a, diluted 1/25 to 1/100; (4) a mouse mono-
clonal antibody against human EGF purified from urine (MAb
126, Chemicon International, Inc.), diluted 1/25 to 1/1,500; (5) a
rabbit antiserum directed against mouse EGF (Sigma Chemical
Co., St Louis, Missouri, USA, diluted 1/1,500 to 1/6,000; (6) a
rabbit antiserum against rat EGF and not cross reacting with rat
TGF-a (RIA-grade; Biomedical Technologies Inc., Stoughton,
Massachusetts, USA), diluted 1/20 to 1/100. TGF-a was visu-
alized using a mouse monoclonal antibody against human
recombinant TGF-a (Ab-2, Oncogene Science), diluted 1/1,500.
Tamm-Horsfall protein was localized using a goat antiserum
against human THP (Organon Teknika, Durham, North Caro-
lina, USA), diluted 1/30,000. Epithelial membrane antigen was
demonstrated using the monoclonal antibodies HMFG1 and
HMFG2 directed against human milk fat globulin [38].
Staining was performed on 4- paraffin sections of "formol-
calcium" or PLP fixed tissue, essentially as described previ-
ously [39]. Briefly, sections were mounted on poly-L-lysine
(molecular weight > 300,000; Sigma Chemical) coated glass
slides, hydrated, and treated for 20 minutes with 0.003% trypsin
(type III, 11,250 U/mg, Sigma Chemical) in 10 mM Tris-HC1
buffer (pH 7.3) containing 0.9% NaCl and 1 m CaC12. After
equilibration in Tris-buffered saline containing 0.1% Triton
X-100 (TBS) and treatment with normal horse serum (1/5) for 20
minutes, the primary antibodies were applied without washing,
and incubation was performed overnight. The sections were
then washed and treated with biotinylated affinity-purified horse
anti-mouse immunoglobulin serum (Vector Laboratories Inc.,
Burlingame, California, USA) for 30 minutes followed by the
avidin/biotin/peroxidase complex (Vector Laboratories Inc.)
for one hour. All dilutions were made in TBS. After extensive
washing, peroxidase was revealed either with 0.02% 3-amino-
9-ethylcarbazole (Sigma Chemical) and 0.002% H202 in 20 mi
acetate buffer (pH 5.2) containing 9.5% dimethyl sulfoxide, or
with 0.5 mg/ml diaminobenzidine and 0.03% H202 in 0.1 M
Tris-HC1 buffer (pH 7.6). The sections were counterstained
with methyl green or hematoxylin and were mounted in Kai-
ser's glycerin/gelatin mounting medium or DPX, respectively.
For frozen sections, the incubation buffer contained 1% BSA
instead of 0.1% Triton X- 100, and endogenous biotin binding
activity was reduced by successive preincubation with avidin
and 0.1 mg/ml biotin. Simultaneous visualization of EGF and
TGF-a on the same section was performed by fluorescence
microscopy, using an FITC-labeled donkey anti-rabbit IgG
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secondary antiserum (Amersham International plc., Amer-
sham, UK) to reveal EGF, and a Texas Red labeled sheep
anti-mouse Ig secondary antiserum (Amersham International
plc.) to reveal TGF-a. Sections were inspected either by
classical fluorescence microscopy or by confocal laser scanning
microscopy.
The specificity of the EGF staining was evaluated by adding
different amounts (from 20 ng to 20 jig) of human recombinant
EGF (Boehringer Mannheim GmbH, Mannheim, Germany),
human recombinant TGF-a (Boehringer Mannheim GmbH), or
THP from human urine (Chemicon International, Inc.) to I
jig/ml anti-EGF IgG (Ab-3) during incubation of the sections.
Likewise, the specificity of the TGF-a staining was evaluated
by preincubating 200 ng/ml of the antibody with 20 ng to 20 jig
human recombinant TGF-a or EGF. Negative controls con-
sisted in replacing the primary rabbit antiserum or mouse
monoclonal antibody with diluted normal rabbit serum or an
irrelevant monoclonal antibody, respectively.
Histochemical staining
Biotinylated peanut agglutinin (E-Y Laboratories, San Ma-
teo, California, USA) was used at 1 /.Lg/ml and binding was
revealed using an avidin-biotinylated peroxidase complex and
peroxidase staining (vide infra). Alkaline phosphatase enzy-
matic staining was performed using 0.025% 5-bromo-4-chloro-
3-indoxylphosphate-p-toluidine salt (Serva Feinbiochemica
GmbH, Heidelberg, Germany) as the substrate and 0.05%
nitroblue tetrazolium (Sigma Chemical Co.) as the chromogen,
according to Gossrau [40], in 0.1 M Tris-HC1 buffer (pH 9.4) to
which was added 1 mM MgC12. Carbonic anhydrase enzyme
activity was demonstrated on 6-ji frozen sections of fixed
tissue, floating on a solution containing 1.75 mrs CoSO4, 53 mM
H2S04, 157 mtsi NaHCO3, 11.7 m KH2PO4, and 10 ppm
Tween 20, according to LOnnerholm [41]. Different fixation
conditions were compared for carbonic anhydrase histochem-
istry: (1) formol-calcium (vide supra); (2) 2% formaldehyde plus
0.2% glutaraldehyde in 0.1 M Na-cacodylate, pH 7.4, during one
hour; (3) 2% glutaraldehyde in 0.1 M Na-cacodylate, pH 7.4,
containing 1% sucrose, during 1 to 24 hours.
Video densitometry
The polarity of EGF and TGF-a staining in individual cells of
different distal tubular segments in the human kidney was
measured by digital image analysis. The equipment consisted of
a Reichert Polyvar microscope, a color video camera (Hitachi
VK-C2000E MOS camera), a screen grabbing card (Screen
Machine, FAST Electronic GmbH, MUnchen, Germany) with
frame grabbing software (SM Camera, version 2.52, ProficomP
GmbH, Karlsruhe, Germany), and an Apple Macintosh com-
puter (Model II CX). Analysis was performed using a public
domain image analysis computer program (Image, version 1.44,
NIH). Eight-bit gray scale pixel values were converted to
optical densities by linear interpolation from a series of gray-
standards, the optical densities of which were determined in a
Beckman spectrophotometer. The optical density was mea-
sured along a 30-pixel (2.3 ji) wide transept in the middle of the
cell, perpendicular to the apical cell surface. All examples for
EGF presented in Figure 3 were taken from a single tissue
section, to allow comparison of the staining intensity between
cell types.
Results
Staining spec jficity
Of all the anti-EGF antibodies tested, only the polyclonal
antiserum Ab-3 from Oncogene Science and monoclonal anti-
body 144-8 from Santa Cruz Biotechnology yielded strong and
consistent staining. Trypsin pretreatment was necessary for
both when used on paraffin sections, For Ab-3, addition of 20 ng
human recombinant EGF to 1 jig anti-EGF IgG abolished
staining in all distal tubular segments beyond the TAL and
DCT. In the latter, staining was also reduced at 20 ng, but 200
ng was necessary to completely eliminate it. Since as much as
20 jig THP purified from human urine had no effect on EGF
staining, it can be excluded that the more persistent EGF
staining in the TAL would be caused by some cross reactivity
with THP, that is abundantly expressed in this segment only.
Addition of up to 20 jig TGF-a had no effect on EGF staining.
Finally, omission of the primary antibody or replacement by
diluted normal rabbit serum abolished the staining pattern.
Similarly, addition of 20 ng EGF to MAb 144-8 abolished
staining in the TAL and DCT.
TGF-a staining was significantly reduced upon addition of 2
jig human recombinant TGF-a and was completely eliminated
when 20 jig was used; the same amount of EGF had no effect.
In addition, the staining pattern for TGF-a obtained in the rat
kidney (data not shown) was identical to that reported by
Walker et al [42] based on the same antibody. Omission of the
primary antibody or replacement by an irrelevant mouse mono-
clonal antibody abolished the staining pattern.
Human kidney
All 11 specimens investigated displayed a consistent segmen-
tal and subcellular distribution pattern; there was also no
difference in either EGF or TGF-a staining between the organ
donor specimen and the samples of normal tissue that were
taken from tumor-affected kidneys. Figure 1A provides a low
magnification overview of the EGF distribution as obtained
with Ab-3 on paraffin sections. Comparisons on adjacent sec-
tions demonstrated that there is only a limited overlap between
EGF and THP staining (Fig. 1B, C). The EGF staining pattern
obtained with monoclonal antibody 144-8 was identical to that
for Ab-3, except for the absence of staining beyond the DCT.
The distribution of EGF (Ab-3), TGF-a, and THP immunore-
activity along the human nephron are summarized in Figure 1D.
Details of the subcellular localization of EGF (Ab-3) and TGF-a
staining in different distal tubular segments are shown in
Figures 2A through H and 3.
Cortex and medullary ray. EGF staining was absent in the
PCT, the medullary ray PST, the glomerular tuft, the epithelium
of Bowman's capsule, and the tubular interstitium (Fig. 1A, B).
In paraffin sections, most of the cells in the TAL were moder-
ately positive with both the polyclonal antiserum Ab-3 and the
monoclonal antibody 144-8, displaying staining predominantly
on the apical cell surface and also in the cytoplasm (Figs. 1B,
2A, and 3); the basal plasma membrane infoldings were nega-
tive. The macula densa was negative. In fact, the segmental and
subcellular distribution of staining for Ab-3 and 144-8 was
indistinguishable. All TAL cross sections were strongly posi-
tive for THP as well (Fig. 1C). The DCT, which started
immediately behind the macula densa and extended to 35 to
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Fig. 1. Human kidney. A. Low-magnification overview, showing the distribution pattern of EGF immunostaining from the capsula to the ISOM,
as obtained with the polyclonal antiserum Ab-3 against human recombinant EGF. B. EGF immunoreactivity (Ab.3) in cortical labyrinth and
medullary ray; note the octopal cells in the C-CD. C. Section adjacent to B, stained for THP. D. Schema of the nephron representing the segmental
distribution of EGF (Ab-3), TGF-a, and THP immunostaining. (A, x 22; B and C, x 125)
40% of the total length of the distal tubule in the cortical cytoplasm but also on the apical cell surface (Figs, 2B and 3).
labyrinth (as determined from the frequency of its profiles), This staining pattern could be confirmed on chioroform-aceton
displayed moderate EGF staining in all cells, mainly in the fixed cryostat sections for both Ab-3 and MAb 144-8. In
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Fig. 2. EGF (antiserum Ab-3) and TGF-a staining in human kidney. Arrows indicate cells that were analyzed by video-densitometry to produce
the profiles presented in Figure 3. A. EGF in ISOM-TAL; B, EGF in DCT; C, EGF in early CNT; U, EGF in late CNT; the number of unstained
cells increases towards the C-CD; E, EGF in ISOM-CD; F, TGF-a in DCT; G, TGF-a in CNT; H, TGF-a in ISOM-CD: positive cells frequently
display intercalated cell morphology. (A through H, X 800)
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Fig. 3. Video-densitometric analysis of the subcellular distribution of
EGF (Ab-3) and TGF-a staining in individual cells of different distal
segments of the human kidney. All examples for EGF were taken from
a single tissue section. The optical density proffles were measured along
a 30-pixel wide transept with the background optical density set to zero.
The X-axis represents the distance in micron from the luminal towards
the basal surface of the cell.
addition, on paraffin sections of formol-calcium or PLP-ftxed
tissue, Ab-3 revealed strong membranous staining in more
distal parts of the nephron. In the remaining 60 to 65% of the
distal tubule in the cortical labyrinth, corresponding to the
CNT, virtually all cells showed strong staining equally distrib-
uted over the entire cell surface (Fig. 2D). Towards the end of
the CNT, an increasing number (25 to 50%) of negative cells
appeared (Fig. 2E). In the C-CD, the number of positive cells
was less than 10% (Fig. 1B); in some cross sections positive
cells were even absent. Staining in these CD cells was strong on
he basal cell surface, with less intense staining on the lateral
md apical cell surfaces. Most of the EGF immunoreactive
C-CD cells displayed a specialized morphology, consisting in
the presence of long lateral extensions in the basal portion of
the cell (vide infra) (Fig. 4).
No TGF-a was seen in the C-TAL, nor in the PCT, glomeruli,
or tubular interstitium. Strong and diffuse cytoplasmic staining
was observed in most of the cells in the DCT (Figs. 2C and 3).
In some cells, staining was stronger at the cell apex. Staining
became less intense and more heterogenous in the CNT (Fig.
2F). The C-CD was moderately to weakly positive but a
minority of cells presented somewhat stronger staining. Immu-
noperoxidase staining sometimes suggested the presence of
nuclear TGF-a immunoreactivity, but this could not be con-
firmed upon confocal laser scanning microscopy.
In contrast to EGF staining (Ab-3) in only a small number of
C-CD cells, strong carbonic anhydrase histochemical staining
appeared in the cytoplasm of virtually all cells lining this
segment. The results obtained with the different tissue fixation
conditions tested were identical.
Outer medulla. With both Ab-3 and MAb 144-8, EGF staining
was seen in the OM-TAL in paraffin as well as in cryosections.
Most of the TAL cross sections in the OSOM and ISOM (Fig.
2A) were moderately positive. As in the cortical TAL, staining
was localized mainly on the apical cell surface but some
positivity was also seen in the cytoplasm; basal plasma mem-
brane infoldings were unstained. Again, Ab-3 revealed the
presence of strong EGF-immunoreactivity in the CD in paraffin
sections. The OSOM-CD displayed a distribution pattern that
was similar to that of the C-CD, with less than 10% of scattered
positive cells. Their number increased in the ISOM-CD to
approximately 50%, as evidenced by an alternation of positive
and negative cells. Like in the C-CD, staining in OSOM- and
ISOM-CD cells was particularly strong at the basal cell surface,
but the lateral cell surfaces were also stained. Apical staining
decreased towards the IM. The PST, TL, and tubular intersti-
tium were negative.
The morphology of the EGF-stained cells (Ab-3) in the
OM-CD, and as already mentioned also in the C-CD, was quite
peculiar. Some cells had a hat-like profile with a narrow apex
0 5 10 15 20 and a broad base, bearing long lateral cytoplasmic extensions
which passed underneath and between neighboring cells (Fig.
Microns 4D, E). When cut tangentially, they displayed a stellate or
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Fig. 4. EGF staining in octopal cells of the human CD, without (B and C) and with (D—G) hematoxylin nuclear counterstaining to reveal the
position of the negative cells in the epithelium. A. Portion of an OSOM-CD as reconstructed from 10 serial sections, illustrating the actual shape
and full dimensions of all positively stained intercalated cells visible at one side of the tubule. The negative principal cells are depicted in part of
the tubule. B, C, and D. Tangential sections through a C-CD, showing the octopus-like morphology of the large intercalated cells. D and E.
Longitudinal section, showing the narrow apex and very broad base of these cells (arrows). F. Tangential sections showing an octopal cell that
embraces almost the entire width of the CD. G. Tangential section through positively stained cells without lateral extensions (arrowheads). (A, x
500; 8, x 800; C through G, )< 500; bar = 40 micron).
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dendritic morphology (Fig. 4B, C, D, and F). The general shape
of these cells resembled that of an octopus, with its body
inserted in the epithelium and reaching the tubular lumen, and
its arms extending along the tubular periphery. The lateral
projections were shorter in the ISOM-CD and variations in their
length were noticed between samples obtained from different
individuals. From a set of ten serial sections with a calculated
thickness of 5.5 j, three-dimensional reconstructions were
performed for 30 randomly selected EGF-positive cells (Ab-3)
in the OSOM-CD (Fig. 4A). This made it possible to trace all
extensions belonging to each cell and thus to determine their
actual size and shape. While the unstained CD cells had an
average width of 6.8 z (N = 50) and a basal area of 36 j2, the
basal surface of the positively stained stellate cells covered an
area of 805 251 2 (mean SD; N = 16), that is, 22 times
larger than the negative cells. The largest one was 38.6 t in
diameter and occupied an area of 1170 Those in Figure 4B
and C are even slightly larger. This corresponds to about 1/4 of
the perimeter of a CD (167 .t). Such cells were never adjacent
and via these extensions they were in immediate contact with 21
3 (N = 7) negative cells. Other positively stained cells had no
cytoplasmic extensions, and their basal area was 217 87 p.2 (N
= 7), that is, still 6 x larger than the negative cells (Fig. 4G).
They occurred frequently in groups of two or three. The
remaining seven cells had an intermediate morphology and
basal area (443 173 p.2). The height of all CD cells was the
same (11.4 p.).
TGF-a was absent from the PST, TL, ISOM-TAL, OSOM-
TAL, and tubular interstitium. The entire OSOM-CD and
ISOM-CD epithelium displayed moderate cytoplasmic staining.
In addition, scattered cells within this epithelium showed some-
what stronger cytoplasmic staining (Fig. 2H); their number was
considerably smaller than the number of EGF stained cells in
these segments. Some of the more positive cells possessed the
lateral extensions that were noticed during EGF staining.
Comparison on adjacent sections and double immunofluores-
cent staining revealed that at least some of these cells were also
positive for EGF. Like in the medullary rays, carbonic anhy-
drase staining was strongly positive in the cytoplasm of most
OM-CD cells.
Inner medulla. In the IM, there was no EGF staining when
MAb 144-8 was used, neither on frozen nor on paraffin sections.
Also Ab-3 was unable to detect any EGF immunoreactivity on
frozen sections. However, on paraffin sections, staining was
seen in the CD. The number of positive cells in the IM-CD1 was
between 50 and 75% and decreased to less than 5% in the
papillary ducts, with many papillary duct cross-sections con-
taining none or only single positive cells. As in the more
proximal CD, staining was localized on the entire cell surface,
but was particularly evident at the cell base, where a broad
band of staining could be seen. Lateral cellular processes were
short or absent. Moderately intense cytoplasmic TGF-a stain-
ing was present in the IM-CD1 and IM-CD2, but the papillary
ducts were negative. Most IM-CD cells were strongly carbonic
anhydrase positive, although the number of negative cells
increased towards the papillary epithelium.
Papilla and ureter. In paraffin sections, Ab-3 occasionally
disclosed membranous EGF staining in a small number (<1%)
of round basal cells in the papillary epithelium. The ureter
epithelium was always negative. TGF-a staining was absent.
Monkey kidney
The EGF distribution pattern for Ab-3 in formol-calcium
fixed paraffin embedded monkey (Macaca fascicularis) kidney
was identical to the human staining pattern, from the TAL to
the papillary epithelium. Moreover, the relative abundance of
positive cells in the different segments and the subcellular
distribution of staining also was similar, consisting of apical and
cytoplasmic staining in the TAL, staining over the entire cell
surface in the DCT and CNT, and strong basal staining in the
CD. As in the human kidney, the EGF-containing cells of the
C-CD and OSOM-CD presented long lateral cellular extensions.
TGF-a could not be detected.
Rodent kidney
To confirm the segmental differences between the distribu-
tion of EGF immunoreactivity in the primate kidney, as ob-
tained with Ab-3 on paraffin sections, and previous data for the
rodent kidney, the staining patterns obtained with an antiserum
against either rat, mouse, or human EGF (Ab-3) were compared
on adjacent sections from rat and mouse kidney that had been
fixed, embedded in paraffin, and stained the same way as the
human material. It appeared that the staining patterns for all
three antisera were identical in the rat kidney: EGF immuno-
reactivity was restricted to the TAL and early DCT (data not
shown). The subcellular distribution of staining was also iden-
tical, as it was strongest in the apical pole of the cells and on the
apical cell surface. A similar analogy in staining distribution
was obtained for the mouse kidney, although the intensity of
staining with the anti-rat and anti-human EGF antisera was low.
Discussion
The immunohistochemical distribution patterns for EGF in
the human kidney suggest that there may be two different forms
of immunoreactivity present. One is expressed by the TAL and
DCT and was detected by both monoclonal antibody 144-8 and
by the affinity-purified polyclonal antiserum Ab-3 against hu-
man recombinant EGF, in frozen sections and in paraffin
sections of formol-calcium or PLP-fixed renal tissue. The other
is localized to the CNT and CD and was picked up by Ab-3 in
formol-calcium or PLP fixed paraffin embedded material. It is
not clear whether this late distal tubular and ductal pool of EGF
immunoreactivity corresponds to a conformation of EGF that is
masked in native material, or alternatively whether it is asso-
ciated with the existence of an EGF-related or -resembling
epitope in these segments. The non-identity of both pools is
further suggested by the observation that the late distal tubular
and ductal staining was more rapidly displaced through compe-
tition with human recombinant EGF. A distal tubular localiza-
tion of EGF is in partial agreement with recent in situ hybrid-
ization data from Lev-Ran et al [43], who demonstrated EGF
mRNA in the human DCT and CD, and also in the nuclei of
glomerular mesangial cells, but they did not detect any EGF
immunoreactivity when using a monoclonal antibody against
human EGF. The match between their EGF mRNA localization
and our immunohistochemical staining patterns reinforces the
validity of the present findings, and it supports a local produc-
tion of the observed immunoreactivity. Earlier immunohisto-
chemical studies on the human kidney are largely contradic-
tory, as staining was found in each histologic compartment.
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Kasselberg et a! [44] reported intense staining in extracellular
portions of the renal medullary interstitium, increasing towards
the papilla and with age. Yoshioka et a! [45] described EGF
staining in glomerular capillary walls, arterioles, and small
arteries, and weak cytoplasmic staining in distal tubules.
Poulsen et a! [46] observed immunoreactivity in some proximal
tubules, whereas Lau, Fowler and Ghosh [47] described cyto-
plasmic staining in proximal, distal, and collecting ducts, and
Kajikawa et al [6] found EGF in tubules which were not
identified, In contrast to these disparities for the human kidney,
there is agreement on the expression pattern of EGF in the
mouse and rat kidney, where several groups have conclusively
identified, by immunocytochemistry and in situ hybridization,
the TAL and early DCT as the only sites of EGF synthesis,
while the macula densa was negative [31, 33, 46, 48, 49]. We
could confirm this distribution pattern, even with the polyclonal
antiserum Ab-3 against human recombinant EGF. Indeed, this
antiserum provided a staining pattern in trypsin-pretreated
sections from formol-calcium fixed paraffin-embedded rat and
mouse kidney that is identical to the staining pattern that has
been reported by several other groups for these species, using
different antisera and different fixation conditions, including
frozen sections. This suggests that the epitope or molecular
configuration of EGF occurring in the human kidney beyond the
DCT is not present in the rat and mouse kidney. Finally, in the
pig, mainly cytoplasmic EGF immunoreactivity was found in
the DCT [50]. Hence, it appears that there is indeed interspecies
homology in the renal distribution pattern of EGF between
humans and rodents, as far as the epitope is concerned that is
recognized by antibody 144-8 and Ab-3 in frozen sections and
by 144-8 in paraffin sections as well. Interestingly, in the rat and
mouse kidney, EGF has an almost perfectly matching co-
localization with Tamm-Horsfall protein [51], with which the
EGF precursor shares 30% structural homology [52].
The presence of long lateral cell projections, as revealed by
Ab-3 on paraffin sections, was an intriguing light microscopical
feature of the large EGF stained cells in the adult C-CD and
OSOM-CD; they were equally evident in the monkey. These
extensions show no resemblance to the pronounced plate-like
cell processes that are present between interdigitating DCT
cells and that are sparce between CNT cells [35, 53]. However,
they fit perfectly the light and electron microscopic descriptions
of Möllendorff [54] and Myers et a! [55], who mention that the
scattered dark or intercalated cells of the human CD bear
processes which partially project between adjacent light cells,
giving the dark cells a starlike shape. As the intercalated cells
constitute a heterogenous population among themselves [35],
additional data are needed to establish whether EGF immunos-
taming is associated with all intercalated cells or only with a
specific cellular phenotype. The substantially larger basal pole
of the stellate cells in the C-CD and OSOM-CD and their
localization partially underneath adjacent cells suggests them to
be type B intercalated cells in these segments, whereas in the
IM-CD they displayed a type A-like cell morphology. Although
carbonic anhydrase expression in the CD is considered as
specific for intercalated cells [35, 56], most cells lining the C-CD
and OSOM-CD were histochemically positive, which is in
agreement with immunohistochemical data from Spicer, Sens
and Tashian [57]. Since the number of carbonic anhydrase
positive cells largely exceeded the number of EGF stained cells
in these segments, it seems that not all intercalated cells contain
EGF immunoreactivity, or alternatively that carbonic anhy-
drase expression in the human CD is not restricted to interca-
lated cells.
Since the name given to a particular cell type is in general
inspired by its most prominent morphological or functional
characteristics, one could envisage a new name for the interca-
lated cell that would better reflect this highly specialized
morphology and its potential functional implications. By coin-
cidence, the German name "Schaltzelle" can be interpreted as
indicating not only the intercalated position of these cells but
also a switching or regulatory role. We propose the term
"octopal cell," since the long cytoplasmic extensions that
irradiate in the basal plane of the cell resemble the arms of an
octopus, creeping under and between many surrounding prin-
cipal cells and probably exerting a modulatory activity upon
them. The term could be applicable to other species as well,
since the rat intercalated cell shows similar features (unpub-
lished data).
Little or no attention has been attributed during the last 25
years to this unique and highly specialized structural feature of
the human intercalated CD cell. The high level of EGF immu-
nostaining on the entire surface of these cells, as described in
this study, made their actual shape particularly apparent. More-
over, as it was EGF with its many paracrine activities or an
EGF-related epitope that was found on their surface, an extra
dimension is added to the potential biological role of these cells.
Indeed, these lateral processes, which are remarkably long for
epithelial cells, obviously raise the question as to what may be
their relevance to the function of the intercalated cell. Since the
extensions were often longer than the diameter of a CD princi-
pal cell, a single intercalated cell can make direct contact with
an average of 21 principal cells that are not necessarily imme-
diately adjacent. In other words, such a cell shape is particu-
larly suited to establish multiple intercellular contacts, remines-
cent of neurons. Hence, it could be related to a regulatory or
coordinating function for the intercalated cell within the CD
epithelium, possibly implicating the EGF immunoreactivity on
its plasma membrane. CD principal cells are involved in Na
reabsorption, K secretion, and ADH-mediated water reab-
sorption, as evidenced by the polar localization of specific
carriers, enzymes, and pumps. Type A intercalated CD cells,
on the other hand, are involved in proton secretion, whereas
type B intercalated cells secrete bicarbonate and reabsorb
chloride [35]. At first glance, none of these intercalated cell
functions would benefit from the existence of long cellular
processes.
Several reports suggest that EGF may modulate water and
electrolyte transport in the collecting duct. A brisk natriuresis
and diuresis takes place after infusion of EGF into the sheep
renal artery, despite a fall in GRF, suggesting that the effect was
tubular and not hemodynamic [58, 59]. When administered
basolaterally to rabbit C-CD fragments, very low concentra-
tions of EGF quickly decrease transepithelial voltage and
Na-reabsorption [60, 61] and inhibit the hydroosmotic effect of
vasopressin [62]. In cultured rat IM-CD, EGF stimulates pros-
taglandin E2 synthesis [16], which is also known to inhibit NaC!
absorption from the TAL and OM-CD. Our present data
indicate that in primates such effects of EGF could be exerted
within the CD epithelium, via intercalated cells and their long
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lateral cell projections on the neighboring water and salt trans-
porting principal cells with which they are in direct cellular
contact, through the production of EGF or a substance contain-
ing an EGF-related epitope. Moreover, in analogy to the effect
of EGF on gastric mucosa [1], EGF or a related epitope could
also modulate the secretion of protons and/or bicarbonate by
the intercalated cells in an autocrine way.
We could previously [26] and presently confirm that in the
rat, like in the mouse, EGF is predominantly associated with
the apical plasma membrane and apical vesicles of the TAL and
early DCT [31, 32, 63]. We now present data indicating that
predominantly apical (membranous) staining also occurs in the
human (and monkey) TAL, and to some extent, in the DCT. In
addition, Ab-3 yielded positivity for EGF on the entire cell
surface of CNT cells and mainly at the basal cell surface of
intercalated cells in the CD. Thus, distal tubular segments
displayed differences, not only in the relative intensity of EGF
staining and in the number of positive cells, but also in its
subcellular localization. A basolateral localization of EGF in
the kidney would constitute a new element in the discussion
regarding the physiological role(s) of renal EGF. Since an apical
localization of EGF is currently considered as the general rule
[34] and since EGF receptors, present in the human proximal
and distal tubule and the cortical and inner medullary CD [64,
65], have an exclusively basolateral localization at least in the
animal kidney [60, 62, 66—69], a straightforward interaction
between renal EGF and its receptor is not evident. However,
membrane-bound precursor forms of EGF [70] and also of
TGF-a [71] may function as ligands to interact with EGF
receptors on adjacent cell types. Hence, ajuxtacrine interaction
would be possible between a basally localized EGF precursor
or EGF-related substance, as presently observed in the human
and primate CNT and CD, and the EGF receptor.
In addition to EGF, we localized TGF-a immunoreactivity in
the distal nephron, in agreement with Mydlo et al [72], who
found immunoreactivity in a few distal tubules and CD, al-
though they failed to detect any TGF-a mRNA. Low constitu-
tive levels of TGF-a have also been reported by Gomella et al
[8]. A similar ambiguity between TGF-a mRNA and peptide
detection exists for the normal rat kidney, where Lee et al [73]
detected TGF-a mRNA whereas others did not, although they
could demonstrate strong cytoplasmic and nuclear immunore-
activity in some but not all the CD cells, as well as apical
staining in the PCT [42]. A possible explanation could be that
this renal TGF-a immunoreactivity does not arise from its renal
synthesis, but, for example, from filtration. The question also
arises as to what may be the biological rationale for the
production and/or the presence of both EGF and TGF-a in the
normal human distal nephron, with colocalization in many cells
of the DCT, CNT, and CD. The two peptides interact with the
same receptor and are therefore functionally interchangeable in
vitro and in vivo [19, 74—76]. However, although they are
cleavage products of membrane-bound precursor molecules [9,
10], only EGF staining was predominantly membrane-associ-
ated whereas TGF-a was exclusively cytoplasmic.
In summary, we presently demonstrated that the two struc-
turally and functionally related growth factors EGF and TGF-a
have partially overlapping immunohistochemical distribution
patterns in the human kidney. Two pools of EGF staining were
detected. One was present along the apical cell surfaces and as
diffuse cytoplasmic staining in the TAL and in the DCT. The
other variant was present along the rest of the distal nephron
and occurred as overall membranous staining in the CNT and as
mainly basal staining in the CD. EGF immunostaining further
revealed the existence of long lateral cell projections in inter-
calated CD cells, clearly revealing the octopal morphology of
these cells and furthermore suggesting a modulatory role for the
intercalated cell within the human CD epithelium.
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